Moderna has pledged never to enforce its coronavirus vaccine patents in selected low- and middle-income countries and is launching a new initiative to give external researchers access to its technology.
The announcement comes amid increasing pressure on the U.S. biotech firm, which pulled in more than $12 billion in 2021, to share its technology with initiatives aimed at…